Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20200105046010N60
IRCT20200105046010N60
Recruiting
未知

In- Vivo Bioequivalence study of Empagliflozin-Metformin tablet (EMPATUS Plus® 25/1000 mg ,Pars Darou Pharma, Iran) with brand drug (Synjardy® 25/1000 mg, Boehringer Ingelheim, Germany) in Iranian healthy

Pars Darou Pharmaceutical Company0 sites24 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBio equivalence test.

Overview

Phase
未知
Intervention
Not specified
Conditions
Bio equivalence test.
Sponsor
Pars Darou Pharmaceutical Company
Enrollment
24
Status
Recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Pars Darou Pharmaceutical Company

Eligibility Criteria

Inclusion Criteria

  • •General health
  • •Body mass index between18\-28
  • •Informed consent
  • •Being at the age of 18\-55 years old

Exclusion Criteria

  • •A history of cardiovascular disease
  • •A history of liver \& kidney disease
  • •Alcohol \& Drug addiction
  • •Hypersensitivity to the drug

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Bioequivalence Study of Empagliflozin/Metformin 5/500 mgThis study is performed on healthy volunteers and drug concentration in plasma is determined..
IRCT20200105046010N95Kharazmi Pharmacy24
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Empagliflozin tablets with brand drug (JARDIANCE® 25 mg, Boehringer Ingelheim , Germany)Bio equivalence test.
IRCT20200105046010N49Pars Darou Pharm. Co.24
Not yet recruiting
Not Applicable
Empagliflozin, Linagliptin tablet 25, 5mg ABIDI (Glorenta 25, 5mg), In- Vivo Bioequivalence in Iranian healthy volunteers.
IRCT20200105046010N4Tabriz University of Medical Sciences24
Not yet recruiting
Not Applicable
Bioequivalence Study of Empagliflozin/Linagliptin 25/5 mg Kharazmi Pharma CoThis study is performed on healthy volunteers and drug concentration in plasma is determined..
IRCT20200105046010N97Kharazmi Pharmaceutical Co24
Not yet recruiting
Not Applicable
Bioequivalence study of Empagliflozin 12.5 mg+ Metformin 1000 mg in 24 healthy male under fasting conditions
IRCT20180620040164N13ACtover Pharmaceutical Co26